Insights
Median is a disrupter in the area of medical imaging analysis. Find out more about what we are doing and how our technology works.
Conferences
18 – 21 mai, 2025ATS 2025
Webinars
Closing the Gap: Strategies for Resolving Imaging Discrepancies in Oncology Drug Trials
Articles
-
[Podcast] – Shaping Results through Imaging: Addressing Variability in Oncology Trials
This is an excerpt from our podcast “Shaping Results through Imaging: Addressing Variability in Oncology Trials”. Listen to full version of the podcast here : Connor Anderson – Project Manager II, Median Technologies: Thank you for joining this podcast. We are going to start the interview by setting the stage. Can you describe the role imaging…
Brochures
eyonis™
End-to-end AI/ML tech-based CADe/CADx SaMD
Scientific publications
Developing a novel computer-aided diagnostic technique based on deep learning and CT images for early HCC diagnosis
According to the AASLD guideline HCC can be diagnosed by imaging examination. However, it shows that contrast-enhanced CT has limited accuracy in the diagnosis of HCC, particularly, small-size HCC lesions (≤ 20 mm) are the most difficult to identify with CT demonstrating sensitivity = 64% [1].
Case studies
Accelerating Site Startups Across the Globe for Oncology Clinical Trial Imaging
White papers
Patient’s Body Composition in Oncology Trials: A Case for Implementation
Developed in collaboration with Syneos Health, this white paper explores the barriers preventing its widespread adoption, including challenges related to clinical evidence, accessibility of assessment tools, usability, and cost-effectiveness.